AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies

WASHINGTON, Oct. 16, 2026 /PRNewswire/ -- Breast cancer is the most common cancer diagnosed in U.S. women. In hormone receptor positive, HER2 negative advanced cases, resistance to first line endocrine therapy is common. An estrogen receptor alpha gene mutation, ESR1m, drives resistance...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.